Dr. Sandra P. Dangelo, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York Downstate Medical Center (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 131
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: State University of New York Downstate Medical Center
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 237662 -
Internal Medicine Physician
NY license 237662
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
- Memorial Hematology Lymphoma Group (216 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 131
- Services billed
- 513
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 401 | 117 |
| Established patient office or other outpatient visit, 40-54 minutes | 29 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imatinib Mesylate | 34 |
| Levothyroxine Sodium Other prescribers in New York, NY | 18 |
| Ondansetron Hcl Other prescribers in New York, NY | 18 |
| Oxycodone Hcl Other prescribers in New York, NY | 14 |
| Amlodipine Besylate Other prescribers in New York, NY | 11 |
| Fentanyl Other prescribers in New York, NY | 11 |
| Prednisone Other prescribers in New York, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $17,046 in total to this clinician.
| EMD Serono, Inc. | $17,024 |
|---|---|
| Novo Nordisk Inc | $22.58 |
| Compensation for services other than consulting (speaking, faculty) | $17,024 |
|---|---|
| Food and Beverage | $22.58 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| EMD Serono, Inc. Dec 31, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPublication Assistance | $11,783 |
| EMD Serono, Inc. Dec 31, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPublication Assistance | $3,400 |
| EMD Serono, Inc. Dec 31, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPublication Assistance | $1,841 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $317,210 in research payments for these studies, mostly to the institutions running them.
- Study of DCC-3014 in combination with avelumab in patients with advanced or metastastic sarcomas
Deciphera Pharmaceuticals Inc. - First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo Inc. · Recruiting · NCT06644755 - Phase II Study of Epacadostat in Combination with Pembrolizumab in Patients with Locally Advanced/Metastatic High Grade Sarcoma
Merck Sharp & Dohme LLC - Phase I/II Study of Gemcitabine and Docetaxel Combined with Immune Checkpoint Blockade (INCMGA00012) in Patients with Advanced Soft Tissue Sarcoma
Incyte Corporation - A Phase II Study of CDK4/6 Inhibition(Palbociclib) Combined with PD-1 Blockade(INCMGA00012) in Patients with Advanced Welldifferentiatedand/or DedifferentiatedLiposarcoma
Incyte Corporation - Spearhead-1
Adaptimmune LLC - Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a P…
Adaptimmune LLC - A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently with an Anti-PD-L1 Antibody (Avelumab) in Patients with Advanced High-grade Sarcoma
EMD Serono Research & Development Institute, Inc. - Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Adaptimmune LLC - Phase II Study of Epacadostat in Combination with Pembrolizumab in Patients with Locally Advanced/Metastatic High Grade Sarcoma
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.